PUBLISHER: TechSci Research | PRODUCT CODE: 2045890
PUBLISHER: TechSci Research | PRODUCT CODE: 2045890
Bacterial Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Patient Age Group, By Distribution Channel, By Route of Administration, By Region & Competition, 2021-2031F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Bacterial Vaccines Market is projected to expand from USD 7.19 billion in 2025 to USD 10.94 billion by 2031, achieving a 7.25% CAGR. Bacterial vaccines are biological agents designed to stimulate active immunity against specific bacterial infections. This growth is driven by the increasing incidence of infectious diseases like meningitis and pneumonia, alongside strong government immunization initiatives, which contributed to an 85% global coverage for the DTP3 vaccine in 2024 according to WHO and UNICEF. However, a major impediment is the intricate and costly cold chain logistics required for vaccine storage and distribution, which often limits market access in developing countries where the disease burden is most severe.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 7.19 Billion |
| Market Size 2031 | USD 10.94 Billion |
| CAGR 2026-2031 | 7.25% |
| Fastest Growing Segment | Injectable Vaccines |
| Largest Market | North America |
Market Driver
A key driver for the bacterial vaccines market is the growing threat of antimicrobial resistance (AMR), positioning vaccines as crucial tools to reduce antibiotic dependence by preventing infections like pneumonia and meningitis. The WHO's October 2024 report indicated that vaccines against 23 pathogens could annually cut antibiotic doses by 2.5 billion, underscoring their essential role in antimicrobial stewardship and national health security. Simultaneously, technological progress in conjugate and recombinant vaccines is broadening market potential through improved serotype coverage and durable immunity. High-valency formulations offer wider protection against various bacterial strains, as demonstrated by Merck's June 2024 FDA approval of a 21-valent conjugate vaccine for pneumococcal disease. These innovations are bolstered by investments like Gavi's 2024 launch of the African Vaccine Manufacturing Accelerator, a US$1 billion initiative to foster vaccine production in emerging markets.
Market Challenge
The global bacterial vaccines market faces a significant restraint due to the stringent cold chain requirements. These vaccines demand precise temperature control throughout their journey, from manufacturing to patient, necessitating specialized storage and transport. In regions with poor infrastructure, ensuring temperature integrity is technically challenging and financially burdensome, raising operational costs and reducing profit margins. This economic strain hinders expansion into price-sensitive developing markets, where logistical overheads diminish ROI. Such infrastructure rigidities impede market penetration, leading to supply chain inefficiencies, vaccine wastage, and restricted access in areas with high disease incidence. Gavi's 2024 report on 10.2 million zero-dose children in lower-income countries exemplifies these persistent access barriers.
Market Trends
The market is significantly influenced by two key trends. Firstly, structural vaccinology combined with AI for antigen discovery is transforming R&D by enabling precise computational design of bacterial immunogens, surpassing traditional empirical approaches. Google DeepMind's AlphaFold 3, for instance, boosts biomolecular interaction prediction accuracy by 50%, accelerating the identification of bacterial protein targets and reducing preclinical attrition rates. Secondly, there's a growing focus on maternal immunization research for Group B Streptococcus (GBS) to decrease neonatal mortality via vertical immunity. This aims to overcome the limitations of inaccessible intrapartum antibiotic prophylaxis in low-resource settings. MinervaX's September 2024 manufacturing scale-up for GBS vaccine trials highlights the sector's commitment to establishing maternal vaccination as a standard for preventing severe neonatal bacterial infections.
Key Market Players
- Pfizer Inc.
- GSK plc
- Novartis AG
- Mylan N.V.
- Sanofi SA
- Boehringer Ingelheim International GmbH.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Bharat Biotech International Ltd
- Serum Institute of India Pvt. Ltd
Report Scope
In this report, the Global Bacterial Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Bacterial Vaccines Market, By Vaccine Type
- Pertussis (Whooping Cough) Vaccines
- Tetanus Vaccines
- Diphtheria Vaccines
- Pneumococcal Vaccines
- Meningococcal Vaccines
- Typhoid Vaccines
- Tuberculosis (TB) Vaccines
- Cholera Vaccines
- Shigellosis Vaccines
- Others
Bacterial Vaccines Market, By Patient Age Group
- Pediatric Vaccines
- Adolescent Vaccines
- Adult Vaccines
- Geriatric Vaccines
Bacterial Vaccines Market, By Distribution Channel
- Government Agencies and Programs
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
- Others
Bacterial Vaccines Market, By Route of Administration
- Injectable Vaccines
- Oral Vaccines
- Nasal Vaccines
Bacterial Vaccines Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Vaccines Market.
Available Customizations:
Global Bacterial Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bacterial Vaccines Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others)
- 5.2.2. By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines)
- 5.2.3. By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others)
- 5.2.4. By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
- 5.3. Market Map
6. North America Bacterial Vaccines Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Vaccine Type
- 6.2.2. By Patient Age Group
- 6.2.3. By Distribution Channel
- 6.2.4. By Route of Administration
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Bacterial Vaccines Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Vaccine Type
- 6.3.1.2.2. By Patient Age Group
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.2.4. By Route of Administration
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Bacterial Vaccines Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Vaccine Type
- 6.3.2.2.2. By Patient Age Group
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.2.4. By Route of Administration
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Bacterial Vaccines Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Vaccine Type
- 6.3.3.2.2. By Patient Age Group
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.2.4. By Route of Administration
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Bacterial Vaccines Market Outlook
7. Europe Bacterial Vaccines Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Vaccine Type
- 7.2.2. By Patient Age Group
- 7.2.3. By Distribution Channel
- 7.2.4. By Route of Administration
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Bacterial Vaccines Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Vaccine Type
- 7.3.1.2.2. By Patient Age Group
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.2.4. By Route of Administration
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Bacterial Vaccines Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Vaccine Type
- 7.3.2.2.2. By Patient Age Group
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.2.4. By Route of Administration
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Bacterial Vaccines Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Vaccine Type
- 7.3.3.2.2. By Patient Age Group
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.2.4. By Route of Administration
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Bacterial Vaccines Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Vaccine Type
- 7.3.4.2.2. By Patient Age Group
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.2.4. By Route of Administration
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Bacterial Vaccines Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Vaccine Type
- 7.3.5.2.2. By Patient Age Group
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.2.4. By Route of Administration
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Bacterial Vaccines Market Outlook
8. Asia Pacific Bacterial Vaccines Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Vaccine Type
- 8.2.2. By Patient Age Group
- 8.2.3. By Distribution Channel
- 8.2.4. By Route of Administration
- 8.2.5. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Bacterial Vaccines Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Vaccine Type
- 8.3.1.2.2. By Patient Age Group
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.2.4. By Route of Administration
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Bacterial Vaccines Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Vaccine Type
- 8.3.2.2.2. By Patient Age Group
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.2.4. By Route of Administration
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Bacterial Vaccines Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Vaccine Type
- 8.3.3.2.2. By Patient Age Group
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.2.4. By Route of Administration
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Bacterial Vaccines Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Vaccine Type
- 8.3.4.2.2. By Patient Age Group
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.2.4. By Route of Administration
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Bacterial Vaccines Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Vaccine Type
- 8.3.5.2.2. By Patient Age Group
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.2.4. By Route of Administration
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Bacterial Vaccines Market Outlook
9. Middle East & Africa Bacterial Vaccines Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Vaccine Type
- 9.2.2. By Patient Age Group
- 9.2.3. By Distribution Channel
- 9.2.4. By Route of Administration
- 9.2.5. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Bacterial Vaccines Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Vaccine Type
- 9.3.1.2.2. By Patient Age Group
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.2.4. By Route of Administration
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Bacterial Vaccines Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Vaccine Type
- 9.3.2.2.2. By Patient Age Group
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.2.4. By Route of Administration
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Bacterial Vaccines Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Vaccine Type
- 9.3.3.2.2. By Patient Age Group
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.2.4. By Route of Administration
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Bacterial Vaccines Market Outlook
10. South America Bacterial Vaccines Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Vaccine Type
- 10.2.2. By Patient Age Group
- 10.2.3. By Distribution Channel
- 10.2.4. By Route of Administration
- 10.2.5. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Bacterial Vaccines Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Vaccine Type
- 10.3.1.2.2. By Patient Age Group
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.2.4. By Route of Administration
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Bacterial Vaccines Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Vaccine Type
- 10.3.2.2.2. By Patient Age Group
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.2.4. By Route of Administration
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Bacterial Vaccines Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Vaccine Type
- 10.3.3.2.2. By Patient Age Group
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.2.4. By Route of Administration
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Bacterial Vaccines Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Bacterial Vaccines Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Pfizer Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. GSK plc
- 15.3. Novartis AG
- 15.4. Mylan N.V.
- 15.5. Sanofi SA
- 15.6. Boehringer Ingelheim International GmbH.
- 15.7. Merck & Co., Inc.
- 15.8. F. Hoffmann-La Roche Ltd.
- 15.9. Bristol-Myers Squibb Company
- 15.10. Bharat Biotech International Ltd
- 15.11. Serum Institute of India Pvt. Ltd
16. Strategic Recommendations
17. About Us & Disclaimer
